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Type 2 diabetes mellitus (T2DM) is increasing worldwide, and it is associated with increased risk of coronary artery disease
(CAD). For T2DM patients, the main surgical intervention for CAD is autologous saphenous vein grafting. However, T2DM
patients have increased risk of saphenous vein graft failure (SVGF). While the mechanisms underlying increased risk of vascular
disease in T2DM are not fully understood, hyperglycaemia, insulin resistance, and hyperinsulinaemia have been shown to
contribute to microvascular damage, whereas clinical trials have reported limited eﬀects of intensive glycaemic control in the
management of macrovascular complications. /is suggests that factors other than glucose exposure may be responsible for the
macrovascular complications observed in T2DM. SVGF is characterised by neointimal hyperplasia (NIH) arising from endothelial
cell (EC) dysfunction and uncontrolled migration and proliferation of vascular smooth muscle cells (SMCs). /is is driven in part
by proinﬂammatory cytokines released from the activated ECs and SMCs, particularly interleukin 6 (IL-6). IL-6 stimulation of the
Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT) pathway is a key mechanism through which EC
inﬂammation, SMCmigration, and proliferation are controlled and whose activationmight therefore be enhanced in patients with
T2DM. In this review, we investigate how proinﬂammatory cytokines, particularly IL-6, contribute to vascular damage resulting in
SVGF and how suppression of proinﬂammatory cytokine responses via targeting the JAK/STATpathway could be exploited as a
potential therapeutic strategy. /ese include the targeting of suppressor of cytokine signalling (SOCS3), which appears to play a
key role in suppressing unwanted vascular inﬂammation, SMC migration, and proliferation.
1. Introduction
Diabetes mellitus (DM) is a group of metabolic disorders
characterised by uncontrollable high blood glucose levels
caused by defects in insulin action, insulin secretion, or both.
/e global prevalence of diabetes has increased from 4.7% in
1980 to 8.5% in 2014 (http://www.who.int/diabetes/global-
report/en/), and in the UK alone, diagnosis of diabetes has
more than doubled in the last 20 years with 3.7 million
diagnosed patients in the UK in 2017 (https://www.diabetes.
org.uk). Approximately 90% of these patients have type 2
diabetes mellitus (T2DM), which confers a 2–4 fold in-
creased risk of developing cardiovascular disease (CVD)
compared to nondiabetes mellitus (NDM) patients and is the
leading cause of death in the diabetic population [1, 2].
Revascularisation using coronary artery bypass grafts
(CABG) is frequently required in T2DM patients as the
diﬀuse nature of their CVD is often multivessel [3], although
it is unclear whether or not T2DM is associated with poorer
outcomes following coronary revascularisation [4, 5]. Sa-
phenous vein graft failure (SVGF) is a signiﬁcant clinical
problem with ∼50% of SV grafts completely occluded at 10
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years, and an additional 25% with signiﬁcant restenosis
[6, 7]. /e UK National Health Service (NHS) spends ap-
proximately £10 billion per year on the management of
diabetes and its complications (https://www.diabetes.org.
uk), thus there is a pressing need to develop innovative
therapies to improve CABG outcome for diabetes patients.
T2DM patients are more susceptible to coronary artery
disease (CAD) independently of glycaemic control [8].
However, while normalising blood glucose levels has been
shown to reduce the incidence of microvascular compli-
cations such as diabetic nephropathy, neuropathy, and
retinopathy [9, 10], there is no substantive evidence of any
positive impact on macrovascular complications such as
coronary artery disease, peripheral arterial disease, and
stroke [11, 12]. /is suggests that management of T2DM
requires more than just glycaemic control and that other
factors are involved in the development of macrovascular
complications [13].
/ere is growing evidence that chronic vascular in-
ﬂammation driven in part by proinﬂammatory cytokines
can drive vascular complications of T2DM [14, 15].
/erefore, it is of interest to investigate how proin-
ﬂammatory cytokines, particularly IL-6 which is elevated in
T2DM, contribute to vascular damage resulting in SVGF
and how suppression of proinﬂammatory cytokine re-
sponses via targeting the Janus kinase (JAK)/signal trans-
ducer and activator of transcription (STAT) pathway could
be exploited as a potential therapeutic strategy.
2. Diabetes and Vein Graft Failure
CABG is a clinical mainstay for revascularisation and can be
beneﬁcial for patients with diabetes. A randomised clinical
study of 300 T2DM patients indicated that CABG was as-
sociated with long survival rates (>10 years) and lower in-
cidences of myocardial infarction as compared to
percutaneous coronary intervention (PCI) procedures [16].
/e autologous long SV is the most commonly used conduit
due to its availability, length, and ease of harvesting.
However, it displays lower long-term patency compared to
grafts from the internal mammary artery (IMA) [6]. Rein-
tervention as PCI or repeat-CABG are also associated with
low survival rates and increased risk of other complications
such as myocardial infarction and stroke. At 10 years,
survival rates for repeat CABG patients are 55–75% and are
associated with 4.7% increased incidence of stroke [17, 18].
SVGF occurs in three interlinked phases: thrombosis,
neointimal hyperplasia (NIH), and accelerated atheroscle-
rosis [19]. While thrombosis accounts for ∼12% of the in-
cidences of vein graft failure that occur within 1 month
postprocedure, atherosclerosis on NIH lesions accounts for
50% of late graft failures [6, 7]. Surgical technique, me-
chanical compression of the vein, anastomotic complica-
tions, and graft sepsis also contribute to restenosis [20].
/e predominant cell type in the vascular wall is the
smooth muscle cell (SMC), which is essential for mainte-
nance of vascular tone through controlled contraction and
relaxation. A single-cell thick layer of endothelial cells (EC)
line the vessel lumen and communicate any changes in
circulating factors or ﬂow to the underlying SMCs [21]. /e
EC layer is often disrupted during the grafting procedure,
leading to EC activation, and the exposure of underlying
SMCs to increased pulsatile ﬂow can also modulate phe-
notype. /is leads to induction of adaptive physiological
healing processes including vascular inﬂammation, SMC
migration and proliferation, and secretion of matrix met-
alloproteinases (MMPs). However, these same processes can
also trigger the development of pathological NIH, charac-
terised by chronic vascular EC inﬂammation and un-
controllable SMC migration and proliferation (Figure 1)
[22]. Importantly, human ECs and SMCs from T2DM pa-
tients already show defects in such cellular functions
compared to cells from NDM patients [23–25]. NIH also
narrows the blood vessel lumen and serves as a foundation
for the development of atherosclerotic plaques, which
contribute to SV restenosis [26]. /ese processes are partly
regulated by proinﬂammatory cytokines such as IL-6, and
high levels of IL-6 have been linked to post-CABG restenosis
[27, 28].
EC activation is an early event in the development of NIH
and thus a potential target to prevent SV restenosis [29].
Surgical manipulation (harvesting and implantation) and in-
creased wall and shear stress during adaptation to the arterial
circulation can damage and activate ECs [30, 31]. Activated ECs
release proinﬂammatory cytokines and chemokines,
e.g., monocyte chemotactic protein-1 (MCP-1), and upregulate
adhesionmolecules including platelet-endothelial cell adhesion
molecule-1 (PECAM-1), intercellular adhesion molecule-1
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1),
P-selectin, E-selectin, and subendothelial Von Willebrand
factor (vWF) [32]. /is leads to a cascade whereby activated
platelets, macrophages, and SMCs further release bioactive
molecules including proinﬂammatory cytokines such as IL-6
which stimulate SMC migration, proliferation, and expression
of MMPs which degrade collagen and elastin, allowing SMC to
invade the lumen (Figure 1) [19]. A study, speciﬁcally using
HSV, demonstrated that MMP-2 activation and MMP-9 ex-
pression is increased in SV segments cultured for 14 days
following surgical injury as compared to freshly excised veins
[33]. Another study has shown that MMP-9 but not MMP-2
was upregulated in HSV organ culture (14 days) and coincided
with the formation of NIH [34]. Consistent with a role for
MMPs in driving NIH, adenovirus-mediated overexpression of
tissue inhibitors of MMPs (TIMPs) isoforms signiﬁcantly has
been shown to reduce NIH in cultured HSV segments over 14
days and in a porcine model of vein graft failure for up to 3
months [35–37]. Persistence of a synthetic SMC phenotype
leads to uncontrolled migration and proliferation and has been
linked to development of pathological NIH [21, 38]. Con-
versely, an inability of SMCs tomigrate and proliferate prevents
adaptation and arterialisation of the vein conduit and has been
linked to SVGF [24]. /us, tight control of SMC phenotypic
switching is a crucial determinant of vein graft patency.
2.1. Hyperglycaemia, Hyperinsulinaemia, and NIH.
T2DM is characterised by hyperglycaemia and hyper-
insulinaemia which can cause EC and SMC dysfunction
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either directly or indirectly through the synthesis of cytokines
and growth factors. In vitro, hyperglycaemia stimulates the
release of IL-6 resulting in human mesangial and tubular cell
proliferation, hypertrophy, and diabetic nephropathy via
enhanced JAK/STAT signalling [39]. Hyperglycaemia also
increases expression of ICAM-1, E-selectin, and VCAM-1 in
human umbilical vein ECs (HUVECs) independently of an
alternative proinﬂammatory stimulus, tumour necrosis factor
alpha (TNF-α) [40, 41]. Sustained hyperglycaemia increased
rat aortic SMC proliferation through downregulation of
protein kinase C βII (PKC βII) [42]. Hyperglycaemic re-
sponses may diﬀer according to species, however, as a study
using human SV-SMC observed no eﬀect of elevated glucose
levels (25mM) on proliferation [23]. In summary, the above
studies suggest that hyperglycaemia may contribute to vas-
cular inﬂammation and cell migration and proliferation, all of
which are key events in the development of NIH in SVGF.
Hyperinsulinaemia can also induce EC and SMC dys-
function through abnormal activation of key signalling path-
ways. During insulin resistance, the phosphatidylinositide-3-
kinase (PI3K) signalling pathway that controls the metabolic
eﬀects of insulin activation is impaired, whilst activation of the
proinﬂammatory, mitogenic extracellular signal-regulated ki-
nase 1/2 (ERK1/2) pathway is enhanced. High concentrations of
insulin (100nM) can stimulate proliferation of human frage-
nicular SMCs cultured from T2DM patients [43] and human
SV-SMCs via the sterol regulatory element-binding transcrip-
tion factor 1 (SREBF1) pathway [44], whilst human SV-ECs are
unaﬀected. High insulin (100nM) concentrations have also been
shown to increase migration of bovine aortic SMCs through
increased activation of ERK1/2 pathway. /is study also ob-
served impaired PI3K pathway [45]./is is contrary to the study
performed in human SV-SMCs where hyperinsulinaemia
(100nM) increased cell migration independently of any PI3K
pathway dysfunction [23]. However, the combination of in-
creased SV-SMC proliferation and migration was enough to
lead to a signiﬁcant augmentation of NIH development ex vivo
[44]. Together, these studies suggest that compensatory
hyperinsulinaemia associated with insulin resistance has stim-
ulatory eﬀects in vascular cell migration and proliferation that
may be detrimental (Figure 1).
2.2. Inﬂammation, NIH, and T2DM. Chronic inﬂammation
is a consequence of T2DM and an important pathophysi-
ological process responsible for NIH and SVGF [15, 46, 47].
Conditions prevalent in T2DM evoke the production of
chemokines, proinﬂammatory cytokines, and adhesion
molecules [48], all of which can modulate cell behaviour.
Figure 1: Cellular and molecular signals linking type 2 diabetes mellitus and neointimal hyperplasia. Type 2 diabetes is associated with circulating
hyperglycaemia and hyperinsulinaemia and increased proinﬂammatory cytokines. Activated endothelial cells upregulateMCP-1, ICAM-1, VCAM-1,
andE-selectin./is increases recruitment of platelets and leukocytes which release IL-6./is key cytokine acts on smoothmuscle cells to activate JAK/
STAT signalling to trigger upregulation of cyclin D1 and matrix metalloproteinases (MMPs) and further increase MCP-1 and ICAM-1 induction.
/ese molecular signatures are characteristic of synthetic smooth muscle cells, leading to the development of neointimal hyperplasia.
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Low-grade chronic inﬂammation found in T2DM is cen-
trally controlled by elevation of proinﬂammatory cytokines
such as interleukin-1 (IL-1), TNF-α, and IL-6, mediating
chronic tissue injury. /ere is also growing evidence that
anti-TNF-α biological drugs used to treat rheumatoid ar-
thritis (RA) can improve insulin sensitivity and reduce in-
sulin resistance in RA patients, raising the possibility that
targeting proinﬂammatory pathways may also have thera-
peutic beneﬁts in T2DM patients [49]. /is review will focus
on IL-6, the plasma concentration of which is approximately
1pg/ml in healthy individuals and increases 2-3 folds in
T2DM [13, 47, 50–53].
/e role of IL-6 in vascular inﬂammation and NIH pa-
thology is supported by multiple in vivo and in vitro studies,
with high levels of IL-6 in patients undergoing CABG cor-
relating with graft occlusion and cardiovascular events such as
stroke, myocardial infarction, and repeat CABG [28, 54, 55].
/e potential utility of IL-6 measurements for predicting
speciﬁc outcomes was shown by the ﬁnding that preoperative
serum levels of IL-6 exceeding 3.8 pg/ml were associated with
a signiﬁcantly higher risk of vein graft occlusion and late
cardiovascular events [54]. In HUVECs and human aortic
endothelial cells (HAECs), IL-6 can induce expression of
ICAM-1 and MCP-1, which are involved in monocyte re-
cruitment to the endothelium [56, 57]. IL-6 also triggers the
release of vascular endothelial growth factor (VEGF) in
HAECs thereby increasing angiogenesis [58], while stimu-
lation of rat thoracic aorta SMCs with IL-6 and TNF-α results
in increased expression of MCP-1 and ICAM-1 [59, 60]. In
addition to its proinﬂammatory eﬀects, IL-6 has been shown
to increase rat thoracic aorta SMCmigration and proliferation
[59, 60]. /is was corroborated in a study using human
carotid andmice aortic SMCs, whereby IL-6 increased STAT3
activation and proliferation of SMCs and augmented MCP-1
and ICAM-1 expression (Figure 1) [61]. Whilst there are
limited in vivo and ex vivo studies which build upon these in
vitro ﬁndings, signiﬁcantly higher levels of IL-6 and other
inﬂammatory mediators (ICAM-1, MCP-1, and TNF-α) have
been found in NIH lesions versus healthy vein in a rat
coronary artery bypass graft model [60]. Given the evidence
demonstrating a critical role of IL-6 in endothelial in-
ﬂammation, SMC migration and proliferation, this pro-
inﬂammatory cytokine represents a potential therapeutic
target for treatment of NIH.
3. IL-6/JAK/STAT Pathway
Given the evidence presented above for elevated IL-6 in
T2DM patients, the correlation of high circulating IL-6 with
poor revascularisation outcomes, and the known vascular
cell aberrancies in T2DM, it is pertinent to review the IL-6
signalling pathway. /is consists of three major parts: re-
ceptor activation, activation of the JAK/STATpathway, and
termination of the cascade via suppressor of cytokine sig-
nalling 3 (SOCS3).
3.1. 4e IL-6 Receptor and Classical versus Trans-Signalling.
IL-6 is a 21–28 kDa glycosylated protein comprising 184
amino acids. Cellular responses to IL-6 are mediated
through a receptor complex consisting of IL-6Rα (CD126)
and glycoprotein 130 (gp130) [62]. IL-6 belongs to a family
of cytokines which also include oncostatin M (OSM),
interleukin-11 (IL-11), cardiotrophin-1 (CT-1), leukaemia
inhibitory factor (LIF), and ciliary neurotrophic factor
(CNTF) [63]. Binding of IL-6 family cytokines to their re-
ceptor complexes involves gp130 homodimerisation (in the
case of IL-6 and IL-11) or heterodimerisation with LIF-R or
OSM-R (in the cases of LIF-β, OSM-α, CNTF, or CT-1-α) to
activate JAK/STAT signalling [63]. Importantly, IL-6 sig-
nalling is implicated in mediating the vascular complications
of diabetes and the development of NIH and accelerated
atherosclerosis responsible for SVGF [47, 52, 60].
/e structure of IL-6 consists of four long and straight
α-helices (helix A, B, C, and D) with three receptor-binding
sites [64]. IL-6 Rα is an 80 kDa glycoprotein consisting of an
extracellular region made up of an N terminal Ig-like do-
main which stabilises the receptor and two CBMs which are
required for IL-6 binding linked to a short intracellular
domain [65] (Figure 2). Gp130 has a similar structure as IL-
6Rα with additional four extracellular domains termed IgG-
like ﬁbronectin-like domains and an intracellular domain
containing box 1 and box 2 regions necessary for signalling
[66]./e receptor also exists in two forms: membrane bound
(mIL-6Rα) and soluble (sIL-6Rα), the latter of which does
not contain an intracellular domain (Figure 3).
IL-6 binds to a speciﬁc transmembrane IL-6Rα expressed
on the surface of target cells, and the IL-6/IL-6Rα complex
binds two molecules of transmembrane protein gp130 to
activate intracellular signalling pathways including JAK/
STAT, ERK1/2, and PI3K [62, 67]. Gp130 is ubiquitously
and constitutively expressed [68]. In contrast, mIL-6Rα
expression is restricted to monocytes, hepatocytes, neutro-
phils, and some B- and T-cell subsets [69]. When the cell
expresses both gp130 and IL-6Rα, this is referred to as
classical signalling [70, 71]. Vascular EC and SMC lack
membrane localised IL-6Rα but are still targets of IL-6
signalling because circulating sIL-6Rα can form a com-
plex with IL-6 and associate with gp130 to activate signalling
during inﬂammation. /is phenomenon is termed trans-
signalling and increases the spectrum of target cells that can
respond to IL-6 (Figure 3). sIL-6Rα is translated from al-
ternatively spliced IL-6Rα mRNA [72]. It is also generated
from proteolytic processing of mIL-6Rα by ADAM10,
ADAM17, and meprin metalloproteinases [73, 74]. Due to
the diﬀerent receptor complexes for IL-6 described above,
this cytokine mediates both anti- and proinﬂammatory
responses though classical and trans-signalling, respectively,
contributing to disease progression [71]. Whilst serum levels
of sIL-6Rα are the same for T2DM and NDM patients, the
elevation in circulating IL-6 means that plasma levels of the
IL-6/sIL-6Rα complex are increased in diabetic patients [75],
raising the likelihood of the signalling pathway being in-
appropriately activated.
3.2. JAK/STAT Signalling. /e JAK/STAT pathway is the
principal signalling pathway triggered by IL-6, whilst it also
triggers activation of ERK1/2 and PI3K, these are
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downstream of JAK and reliant on the recruitment of SH2
domain containing protein tyrosine phosphatase 2 (SHP-2)
[62] (Figure 4). Alterations in JAK/STAT signalling have
been implicated in various complications of T2DM [76].
Binding of IL-6 to the receptor complex induces con-
formational changes in the cytoplasmic domain of gp130
causing JAKs activation [77]. /ere are four JAKs (JAK 1–3
and Tyk2 (tyrosine kinase 2)). JAK proteins have seven Janus
homology (JH) domains [78]. /e JH1 domain at the C
terminus has an intrinsic tyrosine kinase activity and in-
cludes a conserved double Tyr (YY) motif involved in trans-
phosphorylation. /e JH2 domain has Ser/Tyr kinase ac-
tivity which is responsible for regulating the activity of the
JH1 domain [79]. JH3-5 comprise an SH2-like domain, and
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Figure 2: Protein domains in the IL-6 signalling pathway. sIL-6Rα comprises an Ig-like domain and two cytokine-binding modules (CBM).
gp130 also has these three domains at the N-terminus, and these are followed by four ﬁbronectin-like domains (FN-like), a transmembrane
domain (TM), and intracellular box 1 and box 2 domains required for JAK binding and signalling. JAK contains a band 4.1, ezrin, radixin,
moesin domain (FERM), an SH2-like domain, a pseudokinase domain (PK), and a kinase domain. STAT3 contains an N-terminal domain
(NTD), coiled coil domain (CC), a DNA-binding domain (DBD), a short linker region, and then an SH2 domain. For SOCS3, this contains
an NTD, kinase inhibitory region (KIR) which inhibits JAK, SH2 domain, and SOCS box responsible for recruiting components of the E3
ubiquitin ligase complex. Key phosphorylated tyrosine residues (Y) involved in signalling protein activation are indicated.
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Figure 3: IL-6 classical and trans-signalling. (a) In classical signalling, IL-6 binds to a membrane-bound IL-6 receptor molecule in addition
to two ﬂanking gp130 molecules. Signalling through this pathway mediates anti-inﬂammatory signalling and is prevalent in blood cells and
hepatocytes. (b) Trans-signalling occurs on the majority of other cell types, including cells of the vascular walls. Here, a soluble IL-6 receptor
molecule is utilised in combination with two gp130 molecules. /is truncated, soluble IL-6 receptor is responsible for many of the
proinﬂammatory actions of IL-6 in disease.
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JH6-JH7 at the N terminus comprises a FERM domain (band
4.1, ezrin, radixin, moesin), which mediates JAK interaction
with gp130 (box1/2 region) [66] (Figure 2). JAK activation
involves trans-phosphorylation at the conserved double ty-
rosine motif of the JH1 activation loop, causing the activation
loop to shift away from the catalytic site to allow access of
protein substrates and ATP [80]. /e activated JAK in turn
phosphorylates the four most distal membrane tyrosine re-
ceptor motifs (Tyr767, Tyr814, Tyr905, and Tyr915) within the
cytoplasmic tail of gp130 [70]. Subsequently, STAT3 and to a
lesser extent STAT1 are recruited via their SH2 domains to the
phosphorylated tyrosine motifs of gp130 [70] (Figure 4).
/ere are seven STAT isoforms (STAT1-4, 5a, 5b, and 6).
STATs have a basic ﬁve-domain structure consisting of a
coiled coil domain at the N terminus preceded by a DNA-
binding domain, a linker domain (which links the DNA-
binding domain to an SH2 domain), an SH2 domain, and a
transactivation domain at the C terminus (Figure 2). STAT
activation requires phosphorylation at Tyr701 for STAT1 and
Tyr705 for STAT3 in the C terminal trans-activation domain
[81]. /e activated STATs then dimerise and translocate to
the nucleus where they bind to two types of response ele-
ments: interferon-stimulated response elements (ISREs) and
gamma-activated sites (GAS). /e ISRE appears to be re-
stricted to IFN signalling, whereas the GAS, including sis-
inducible element (SIE), acute-phase response element
(APRE), and other GAS-like sequences are present in
promoters of genes such as the acute-phase proteins that are
well-deﬁned STAT targets [81]. /e phospho-Tyr759 motif of
gp130 is involved in recruitment of the key negative
modulator of IL-6 signalling, SOCS3. Tyr759 is also necessary
for recruitment of SHP-2 which leads to activation of ERK1/
Figure 4: /e IL-6–JAK/STAT–SOCS3 signalling pathway. /e principal signalling pathway triggered by IL-6 is the JAK/STAT
pathway (orange). JAK phosphorylates gp130 leading to phosphorylation and dimerisation of STAT, which translocates to the nucleus
to induce expression of prosurvival and proinﬂammatory genes. It also induces expression of SOCS3 as a negative feedback loop to
switch oﬀ the signalling pathway (green). SOCS3 forms part of the E3 ubiquitin ligase complex to ubiquitinate JAK, leading to
proteasomal degradation and termination of the signalling cascade. JAK can also act independently of STAT to trigger additional
mitogenic and growth-promoting eﬀects via the PI3K/Akt and ERK1/2 pathways (blue). Sites of action of speciﬁc therapeutic
inhibitors are indicated in red boxes.
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2 and PI3K pathways. However, IL-6 signals through JAK/
STAT3 to mediate the majority of its physiological eﬀects
[69].
3.3. Suppressor of Cytokine Signalling 3 (SOCS3). SOCS
genes encode a family of 8 intracellular proteins (SOCS
1–7 and cytokine inducible SH2 (CIS)) with SOCS1 and
SOCS3 being the most well studied [82]. SOCS proteins
are generally expressed at low concentrations under basal
conditions but are rapidly induced by IL-6 stimulation.
As a result, induced SOCS3 can block IL-6/JAK/STAT
activity to form a classic negative feedback loop. Other
stimuli that induce SOCS3 include cyclic AMP [83],
erythropoietin (EPO), growth hormone, insulin, gran-
ulocyte macrophage colony stimulating factor (GM-
CSF), prolactin, leptin, interferons (IFNs), IL-2, and
IL-9 [82]. Whilst they are undoubtedly beneﬁcial in
dampening inﬂammatory responses, they have also been
implicated in impairing glucose tolerance and thus have a
complex relationship with T2DM [84].
All SOCS proteins have a similar structure that include a
conserved C-terminal SOCS box domain (which is essential
for assembly of a functional E3 ubiquitin ligase complex
required for ubiquitylation of target proteins) and a con-
served central SH2 domain which is essential for binding to
Tyr-phosphorylated motifs in target proteins [85]. Another
component of SH2 domain is the PEST sequence (Pro-Glu-
Ser-/r-rich) which controls the biological half-life of
SOCS3 [86, 87]. SOCS1 and SOCS3 also contain a kinase
inhibitory region (KIR) in the N terminal region of the
protein which is responsible for inhibiting JAK activity [88]
(Figure 2).
SOCS3 inhibits IL-6-induced JAK/STAT activation
through direct inhibition of JAK kinase activity, preventing
both substrate and ATP binding. SOCS3 uses its SH2 do-
main to bind phosphorylated Tyr759 on the cytoplasmic tail
of gp130 and uses the reverse face of the SH2 domain to bind
to the JAK kinase domain around a glycine-glutamine-
methionine (GQM) sequence in the JH1 domain [89].
/e simultaneous binding of SOCS3 to both the cytokine
receptor and JAK is thought to explain SOCS3 selectivity in
inhibiting certain cytokines that signal through gp130.
SOCS3 targets a unique GQM motif found in JAK1, JAK2,
and Tyk2, but not JAK3 [90]. Once bound, the SOCS box
domain in SOCS acts as a scaﬀold for assembly of a mul-
tisubunit E3 ubiquitin ligase complex to target JAKs for
ubiquitylation and proteasome-dependent degradation [91],
thus terminating the JAK signalling cascade. /e E3 ubiq-
uitin ligase complex is made up of cullin5, elongin B/C, and
RING box-2 (Rbx2) and SOCS box [92]./e formation of an
E3 ubiquitin ligase complex is the ﬁnal step in attachment of
ubiquitin to SOCS substrate; this complex adds Lys48-linked
chains of ubiquitin (a highly conserved 76 amino acid
protein) to Lys residues on target proteins (e.g. JAKs), which
serves as a marker for recognition and degradation by the
proteasome [93].
/e eﬀects of SOCS3 are limited by its short biological
half-life which is cell-dependent, for example, 30 minutes in
mouse-derived Ba/F3 hematopoietic cells [94] and 2 hours in
monkey-derived COS-7 cells [95]. SOCS3 protein stability is
regulated by both proteasomal and nonproteasomal deg-
radation pathways. Several studies have shown that non-
proteasomal degradation involves the PEST sequence, a 35
amino acid unstructured Pro-Glu-Ser-/r-rich sequence
found in the SH2 domain of SOCS3 which does not aﬀect
binding to Tyr-phosphorylated cytokine receptor. /is se-
quence has a destabilising role in SOCS3 as removal of this in
HEK293T cells increased SOCS3 stability [96]. Another
mechanism controlling stability of SOCS3 is phosphoryla-
tion of the SOCS box at Tyr204 and Tyr221 which reportedly
enhanced proteasome-dependent SOCS3 degradation in
COS-7 cells [95]. Disruption of the interaction between
elongin B and C with the SOCS box destabilised SOCS3
protein expression [95]. Studies in murine Ba/F3 hemato-
poietic cells identiﬁed that the N-terminal eleven amino
acids in SOCS3 were crucial for destabilisation. In particular,
Lys6 was identiﬁed as a key residue that regulates SOCS3
ubiquitylation and stability [94].
4. Opportunities for Therapeutic Applications
It is clear that atherosclerosis, NIH, and SVGF are sub-
stantial clinical issues, which can be exacerbated in T2DM.
Currently, the only pharmacological treatment available for
graft restenosis is antiplatelet therapy [97]. However, this
does not consistently inhibit the development of NIH [98].
Furthermore, some drug-eluting stents used during PCI
inhibit re-endothelialisation and so can increase the risk of
thrombosis [99, 100]. For example, in a ﬁve-year randomised
clinical trial examining sirolimus-eluting stents in 1,748 DM
patients, probable stent thrombosis after 1 year was doubled
compared to control bare-metal stents group [101]. /ere-
fore, there is a need for agents that selectively inhibit NIH
without altering EC migration and proliferation.
Many promising approaches to target IL-6/JAK/STAT
signalling pathway have been explored; however, they are
not without diﬃculties. /ese include neutralising anti-
bodies which target IL-6 or IL-6Rα, JAK inhibitors, and
STAT inhibitors.
4.1. IL-6/IL-6R Blockade. As the IL-6/sIL-6Rα pathway ac-
tivates the proinﬂammatory trans-signalling in EC and
SMC, studies have examined whether blockade of this
pathway is a feasible clinical treatment. An in vitro coculture
model of human EC and SMC was utilised to examine the
eﬀects of IL-6 signalling pathway inhibitors, namely, sir-
ukumab (anti-IL-6 antibody), tocilizumab (anti-IL-6Rα
antibody), and tofacitinib (JAK inhibitor) in vascular in-
ﬂammation under atherogenic conditions. Cells were cul-
tured under proatherogenic ﬂow conditions in the presence
of TNF-α and oxLDL and then stimulated with sIL-6Rα.
Proinﬂammatory responses were dampened by sirukumab
and tocilizumab, with a signiﬁcant reduction in adhesion
molecule gene expression and an increased contractile SMC
phenotype. Importantly, tofacinitib was less eﬀective in
modulating SMC phenotype and inﬂammation, suggesting
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that inhibiting the initial pathway trigger may have greater
anti-inﬂammatory and vascular protective eﬃcacies versus
targeting of downstream signalling molecules [102].
Tocilizumab is a humanised monoclonal antibody
against both membrane-bound and sIL-6Rα [103]. /is
agent was approved by the Food and Drug Administration
(FDA) in 2010 for treatment of RA and in 2011 for treatment
of systemic juvenile idiopathic arthritis. It is given by in-
jection intravenously and/or subcutaneously [104] and has
undergone limited evaluation for eﬃcacy in CVD. A recently
completed phase II clinical trial examined its ability to re-
duce acute vascular inﬂammation in nonS/T-elevation
myocardial infarction (NSTEMI) patients; however, the
anticipated cardioprotective eﬀect was not clear-cut, with
tocilizumab causing a selective upregulation of in-
ﬂammatory mediators interferon gamma-inducible protein
10 (IP-10) and macrophage inﬂammatory protein-1β (MIP-
1β) [105]. Given that many patients undergoing CVD in-
terventions already suﬀer from underlying chronic in-
ﬂammation observed in conditions such as T2DM, this
potential proinﬂammatory eﬀect may limit its usefulness in
the clinic. Furthermore, this clinical trial was not able to fully
recapitulate the eﬀects of tocilizumab that were evident in
vitro [105].
/ere are also neutralising antibodies against IL-6 in
clinical trials which include olokizumab and sirukumab for
rheumatoid arthritis and cancer, but these are not evaluating
cardiovascular outcomes. However, the main limitation of
neutralising antibodies targeting either IL-6 or IL-6Rα is that
they inhibit classical and trans-signalling nonselectively
[106]. Eﬀorts to selectively block proinﬂammatory trans-
signalling that has been implicated in CVD has led to the
development of a recombinant-engineered Fc-sgp130 fusion
protein. Normally, a combination of sIL-6Rα and sgp130
results in antagonistic activity, and therefore, a complex of
IL-6, sIL6-Rα, and Fc-sgp130 fusion protein reduces IL-6
bioavailability [107]. /is approach is currently in phase II
clinical trials for management of alcoholic liver disease and
chronic hepatitis C virus infection [108].
4.2. JAK/STAT Inhibition. Low molecular weight orally
bioavailable JAK inhibitors are being explored in the clinic
for speciﬁc indications. Tofacitinib is a ﬁrst-generation
nonselective JAK inhibitor with a pyrrol (2, 3-d) pyrimi-
dine derivative which was approved by the FDA in 2012 for
treatment of RA [104]. It inhibits JAK1, JAK2, and JAK3
proteins with low nM potencies (IC50 � 0.16 nM, 0.58 nM
and 1.6 nM respectively) with a 30-fold decrease in potency
at Tyk2 (IC50 � 4.8 nM) compared to JAK1 [109]. Although
phase III clinical trials for Tofacitinib showed an increased
risk of cellulitis, herpes zoster, a decrease in neutropenia and
increased levels of low- and high-density lipoproteins, this
drug is still used due to lack of novel agents available to block
the deleterious eﬀects of IL-6 [110]. /ere are no cardio-
vascular risks reportedly associated with tofacitinib
[111, 112], although trials examining speciﬁc beneﬁts under
pathological cardiovascular conditions are yet to be re-
ported. Ruxolitinib is another orally bioavailable ﬁrst-
generation JAK inhibitor. Ruxolitinib has high potency at
sub-nM range for JAK1 (IC50 � 0.09 nM) and JAK2 (IC50 �
0.036 nM). /is drug was approved by the FDA in 2011 for
management of polycythemia vera and myeloﬁbrosis [113].
Second-generation JAK inhibitors and also STAT inhibitors
are currently in clinical trials (reviewed by [114, 115]), al-
though these are at an early stage.
Accelerated JAK/STAT activation has been implicated
in pathologies such as restenosis in PCI and SVGF,
atherosclerosis, and inﬂammatory disease [70, 116]. Ac-
tivation of STAT3 by JAK1 and JAK2 particularly has been
found to regulate SMC migration and proliferation
[117, 118]. STAT3 leads to transcription of IL-6-
responsive genes such as cyclin D1 (involved in SMC
proliferation), survivin (an antiapoptotic protein that
reduces SMC death), VEGF (responsible for angiogene-
sis), and MCP-1 leading to leukocyte inﬁltration
[56, 116, 119–121]. As such, STAT3 is considered to
contribute to the development of NIH and SVGF, and
accordingly, a considerable body of research has tried to
identify selective therapeutic inhibitors of STAT3. /ese
have principally been as treatments for malignancy, in-
ﬂammation, and autoimmune diseases. Small molecules
targeting SH2-binding domains (necessary for STAT3
binding to the receptor and STAT3 dimerisation) and
STAT-binding site oligonucleotide decoys are strategies
that have been explored to inhibit STAT3 activation in
clinical trials (reviewed by [115]). /e small molecule
STAT3 inhibitor OPB-31121 was tested in a clinical trial
for advanced solid tumours; however, limited eﬃcacy and
unfavourable side eﬀects including peripheral neuropathy
were reported [122], which would limit its use for CVD in
the T2DM population. Other STAT3 inhibitors such as
HL237 and Ionis antisense therapy are currently un-
dergoing clinical trials for autoimmune diseases and
cancer (ClinicalTrials.gov ID NCT03278470 and
NCT01563302, respectively). However, these are at an
early stage and whether cardiovascular risk or beneﬁt will
be measured is unknown.
It is important to note that both JAKs and STATs are
coupled to a number of other cytokines [71] important for a
range of physiological functions. For example, JAKs also
couple to IL-2R [123]. IL-2 is required for immune T-cell
activation [124] and thus JAK inhibitors could be considered
immunosuppressive. Whilst this is beneﬁcial for patients
with a hyperactive immune system (e.g., RA), it may not be
appropriate for CVD and SVGF due to the increased risk of
infections in an already vulnerable patient population.
/erefore, the downstream signalling of IL-6-dependent
gp130/JAK/STAT signalling (e.g., SOCS3) could represent
a more speciﬁc target for reducing SVGF.
4.3. SOCS3 Upregulation. /e protective role of SOCS3 in
limiting vascular inﬂammation is well established [70]. A
central component of this is the ability of SOCS3 to limit IL-
6 signalling [120] and thus protect against NIH and CABG
restenosis, and other inﬂammatory diseases such as ath-
erosclerosis [61]. Mice lacking SOCS3 develop a chronic
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inﬂammatory response induced by IL-1β, whereas mice
lacking both IL-6 and SOCS3 or IL-6 only were protected
from this inﬂammatory response, demonstrating the eﬃcacy
of IL-6 blockade by SOCS3 in vivo [125].
Immunohistochemical analysis of balloon-injured
porcine coronary arteries indicated loss of SOCS3 in
NIH as compared to media [126]. However, SOCS3 has
been shown to be upregulated in human carotid athero-
sclerotic plaques and colocalised with markers for mac-
rophages and SMCs [61]. /is was thought to be a
compensatory mechanism that was insuﬃcient to inhibit
molecular processes leading to development of vascular
remodelling. /e same study found that deletion of SOCS3
by small interfering (si) siRNA in Apo E−/−mice resulted in
a signiﬁcant increase in atherosclerosis lesion size in the
aorta as compared to controls (conﬁrming the protective
role of SOCS3) and signiﬁcantly increased SMC and
macrophage proliferation in vitro [61]. Conversely, over-
expressing SOCS3 via adenovirus transduction in a rat
model of vein grafting had a beneﬁcial eﬀect with a re-
duction in SMC migration, proliferation, and in-
ﬂammatory markers (IL-1β, IL-6, MCP-1, ICAM-1, and
TNF-α), accompanied by a reduction in NIH [60]. Taken
together, these studies indicate that lack of SOCS3 is a
major contributor to enhanced signalling in CVD causing
NIH and restenosis, and its induction may indeed be of
beneﬁt.
One possible mechanism by which SOCS3 reduces cell
migration is by promoting the ubiquitylation and sub-
sequent proteasomal degradation of focal adhesion kinase
1 (FAK 1) [127]. FAK 1 is a nonreceptor protein-tyrosine
kinase involved in integrin-mediated adhesion and reg-
ulates cell motility [128]. /ese studies all highlight the
beneﬁcial role of SOCS3 in limiting inﬂammation and
vessel remodelling; however, the short half-life of SOCS3
in vivo limits its therapeutic potential.
Diﬀerent approaches targeting SOCS3 to increase its ef-
ﬁcacy and function have been tested. /erapeutic trials using
adenoviral delivery of SOCS3 have been reported in
experimental arthritis. Injection into the ankle joints of mice
with collagen or antigen-induced arthritis signiﬁcantly
inhibited the severity of arthritis and joint inﬂammation
[129], showing that the approach is viable (at least in animal
models). Adenoviruses have attracted much attention in gene
therapy because they mediate transient gene expression and
can be made replication incompetent, hence no expression of
viral proteins after transduction. More recently, adenoviruses
encoding TIMP3 have been shown to be eﬀective in blocking
short- (28 days) and long-term (3 months) NIH in pig models
of vein graft failure [33, 36, 37]. Gene therapy is particularly
an attractive option for the treatment on graft restenosis as it
can speciﬁcally target local inﬂammation, migration, and
proliferation. Furthermore, there is a windowwhere the blood
vessel is outside the body before implantation during which
time it can be treated. Replenishment of SOCS proteins by
exogenous administration of recombinant, cell-penetrating
versions of SOCS3 has also been shown to reduce in-
ﬂammation in vivo. SV blood plasma levels of IL-6 and TNF-α
were measured before and after treatment with cell-
penetrating SOCS3 from C3H/HeJ mice with levels signiﬁ-
cantly inhibited after treatment [130]. Furthermore, endog-
enous SOCS3 can be increased in response to cyclic AMP
elevation to inhibit EC inﬂammation in vitro [83].
It is clear from these studies that restoration of SOCS3
can be achieved and has great potential in limiting vascular
inﬂammation and SMC migration and proliferation. /us,
SOCS3 is a promising therapeutic target for reducing NIH
and SVGF. Indeed, it has been proposed to be eﬀective in
ameliorating some of the microvascular complications of
diabetes, namely, nephropathy in in vitro and in vivo studies
in rat [39]. Whether this could be translated into the
macrovasculature and human disease remains to be seen.
5. Conclusion
Deregulation of the IL-6–JAK/STAT–SOCS3 pathway is
implicated in the development of CVD, in particular in
SVGF and NIH. Given that both SVGF and NIH are more
Table 1: Selected IL-6–JAK/STAT–SOCS3 modulators and their impact on cardiovascular disease.
Agent Mode of action Type of study Outcome
Sirukumab IL-6-blocking antibody In vitro ↓ Adhesion molecule expression↑ SMC contractile phenotype
Fc-sgp130 IL-6 trans-signalling inhibitor In clinic Awaiting outcome
Tocilizumab IL-6Rα-blocking antibody to inhibit classical andtrans-signalling
In vitro
In clinic
↓ Adhesion molecule expression↑ SMC contractile phenotype
Approved for rheumatoid arthritis and systemic
juvenile idiopathic arthritis↑ IP-10 and MIP-1β in acute phase STEMI
Tofacitinib JAK inhibitor In clinic Approved for rheumatoid arthritisNo eﬀect on cardiovascular risk
Ruxolitinib JAK inhibitor In clinic Approved for polycythemia vera and myeloﬁbrosisno studies reporting on cardiovascular system
OBP-31121 STAT3 inhibitor Clinical trial ↑ Peripheral neuropathy no studies reporting onthe cardiovascular system
Adenoviral
SOCS3 Increases SOCS3-mediated inhibition of signalling In vivo
↓ SMC inﬂammation, migration, and proliferation↓ NIH
Selected existing therapies targeting the IL-6–JAK/STAT–SOCS3 signalling pathway. Please see text for detail and references.
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common in the T2DM population, and the alarming rate at
which T2DM is increasing globally, there is an urgent need
for the development of new therapeutic strategies to
counteract CVD. Development, testing, and approving of
new therapies is a notoriously time-consuming process,
and so it may be necessary to repurpose existing thera-
peutics for other disorders in the cardiovascular ﬁeld.
Accordingly, the potential eﬀects of existing therapies
targeting this pathway on cardiovascular outcomes are
listed in Table 1.
With the oﬀ-target eﬀects inherent to IL-6 inhibition
(blocking both classical and trans-signalling) and JAK/STAT
inhibitors, it is likely that new therapeutics will evolve from
SOCS3. /e anti-inﬂammatory, antimigratory, and anti-
proliferative eﬀects of SOCS3 in vitro and in vivo high-
light its potential as a therapeutic option in NIH and SVGF.
It will be exciting to see whether this can successfully
translate into the clinic over the coming years.
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